PMID- 35183790 OWN - NLM STAT- MEDLINE DCOM- 20220614 LR - 20220728 IS - 2210-741X (Electronic) IS - 2210-7401 (Linking) VI - 46 IP - 5 DP - 2022 May TI - Effects of image-guided adaptive radiotherapy combined with hepatic artery chemoembolization in primary liver cancer patients. PG - 101889 LID - S2210-7401(22)00032-8 [pii] LID - 10.1016/j.clinre.2022.101889 [doi] AB - OBJECTIVE: The study aimed to explore the effects of image-guided adaptive radiotherapy combined with hepatic artery chemoembolization on the immune function of primary liver cancer patients. METHODS: The study included 84 primary liver cancer patients who received treatment at our hospital between April 2018 and January 2020. They were divided into the control group (n=42, hepatic artery chemoembolization) and the study group (n=42, image-guided adaptive radiotherapy combined with hepatic artery chemoembolization) using the random number table method. AFP, ALT, AST, CA724, CA242 and immune function before and after treatment were compared in the two groups and the short-term efficacy and adverse events (AEs) were statistically analyzed. The two groups were followed up. RESULTS: After treatment, the study group had a higher ORR and DCR compared to the control group, and the difference was statistically significant (P < 0.05). There was no statistical difference in the levels of AFP, ALT, AST, CA724 and CA242 between the two groups before treatment (P > 05). After treatment, the study group had lower levels of AFP, ALT, AST, CA724 and CA242 than the control group, and the difference was statistically significant (P < 0.05). There was no statistical difference in the levels of CD4(+), CD8(+), and CD4(+)/CD8(+) before treatment in the two groups (P > 05). After treatment, the study group had higher levels of CD4(+) and CD4(+)/CD8(+) but lower levels of CD8(+) compared to the control group, and the difference was statistically significant (P < 0.05). In the study group, 2 patients developed radiation-induced liver disease, and the incidence was 4.76% (2/42), which occurred at 4 and 6 weeks after the end of radiotherapy, respectively. The patients mainly had elevated transaminases, ascites, and liver enlargement and hepatoprotection and nutritional support were provided, and the patients gradually recovered after treatment. There was no statistical difference in the incidence of AEs between the two groups (p > 0.05). All patients in the study completed follow up and the follow up completion rate was 100%. The median duration of follow up was 22.5 months. In the study group, 12 of 42 patients (28.57%) died and 21 cases (50.00%) had recurrence. In the control group, 21 of 42 cases (50.00%) died and 27 cases (64.29%) recurred. At 1 year, there was no statistical difference in ORR and DCR between the two groups (P > 0.05) and at 2 years, the study group had a higher ORR and DCR than the control group, and the difference was statistically significant (P < 0.05). CONCLUSION: Image-guided adaptive radiotherapy combined with hepatic artery chemoembolization may improve the immune function of primary liver cancer patients and is of important clinical application value. CI - Copyright (c) 2022 Elsevier Masson SAS. All rights reserved. FAU - Zhao, Yingchun AU - Zhao Y AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. FAU - Zhang, Changwang AU - Zhang C AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. FAU - Zhang, Yongqian AU - Zhang Y AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. FAU - Bo, Changwen AU - Bo C AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. FAU - An, Yonghui AU - An Y AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. FAU - Li, Na AU - Li N AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. FAU - Ma, Wenhua AU - Ma W AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. FAU - Zou, Changpeng AU - Zou C AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. FAU - Zhao, Liping AU - Zhao L AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. FAU - Zhang, Sujing AU - Zhang S AD - Department of Oncology, The First Hospital of Hebei Medical University, No.89 Donggang Road, Yuhua District, Shijiazhuang 050031, China. Electronic address: 123959555@qq.com. LA - eng PT - Journal Article DEP - 20220218 PL - France TA - Clin Res Hepatol Gastroenterol JT - Clinics and research in hepatology and gastroenterology JID - 101553659 SB - IM MH - *Carcinoma, Hepatocellular/drug therapy/radiotherapy MH - *Chemoembolization, Therapeutic MH - Hepatic Artery MH - Humans MH - *Liver Neoplasms/drug therapy/radiotherapy MH - Treatment Outcome OTO - NOTNLM OT - Effect OT - Hepatic artery chemoembolization OT - Image-guided adaptive radiotherapy OT - Immune function OT - Primary liver cancer COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/02/21 06:00 MHDA- 2022/06/15 06:00 CRDT- 2022/02/20 20:31 PHST- 2021/12/20 00:00 [received] PHST- 2022/01/25 00:00 [revised] PHST- 2022/02/14 00:00 [accepted] PHST- 2022/02/21 06:00 [pubmed] PHST- 2022/06/15 06:00 [medline] PHST- 2022/02/20 20:31 [entrez] AID - S2210-7401(22)00032-8 [pii] AID - 10.1016/j.clinre.2022.101889 [doi] PST - ppublish SO - Clin Res Hepatol Gastroenterol. 2022 May;46(5):101889. doi: 10.1016/j.clinre.2022.101889. Epub 2022 Feb 18.